Drug Trial Radar · NCT07880886
Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever
Last checked: Nov 20, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
May 2029
Study completion Apr 2030
Sponsor
- Lead sponsor
- R-PharmIndustry
- Sponsor type
- Industry
- First posted
- Oct 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 5 years, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to evaluate the main pharmacokinetic (PK) parameters, efficacy, and safety of goflikicept (GFC) in children and adolescents with colchicine-resistant or colchicine-intolerant familial Mediterranean fever (FMF).
Conditions
- Familial Mediterranean Fever
- FMF
Interventions
RPH-104Biological
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum serum concentration of goflikicept (Cmax (W16))Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)
- Area under serum concentration-time curve for goflikicept (AUC(0-W16))Time frame: Visit 1 (Baseline) to Visit 10 (Week 16)
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Federal State Budgetary Scientific Institution "V.A. Nasonova Research Institute of Rheumatology
Moscow, Russia
State Budgetary Institution of Healthcare of the City of Moscow "Morozovskaya Children's City Clinical Hospital of the Moscow City Health Department" (GBUZ "Morozovskaya DGBK DZM")
Moscow, Russia
LLC "Medical Technologies"
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.